140 results
DEFA14A
AUPH
Aurinia Pharmaceuticals Inc
3 Jun 24
Additional proxy soliciting materials
6:28pm
or, if an Employee or other Service Provider, ceases to be employed or engaged by the Company upon termination of employment or service, for any reason … employee benefit plan) of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing more than fifty percent
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc
2 May 24
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
6:03am
%.
Aurinia rapidly completed its corporate restructuring in the first quarter, reducing employee headcount by approximately 25%. The Company … barriers to care among LN patients, (Diversity, Equity and Inclusion) DE&I practices, employee engagement, and risk management. The full report is available
8-K
EX-99.1
evp 59tuns
15 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
6:06am
8-K
EX-10.1
uk5d8l
21 Sep 23
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director
4:06pm
8-K
yzt4162i1u 6q1
21 Sep 23
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director
4:06pm
8-K
3koqgabzns44b29gf5
21 Aug 23
Dr. Daniel G. Billen appointed Chair of the Board of Directors
4:11pm
8-K
EX-99.1
d9y54lwllzpn
3 Aug 23
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
6:03am
S-8
ty1 oi1axk
26 May 23
Registration of securities for employees
4:39pm
8-K
EX-99.1
s2478047 rir75u
4 May 23
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
6:06am
PX14A6G
r7g0q6 maxm4yettwcf5
26 Apr 23
Letter to shareholders
10:20am